317 related articles for article (PubMed ID: 12869422)
1. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase.
Stiborová M; Frei E; Sopko B; Sopková K; Marková V; Lanková M; Kumstýrová T; Wiessler M; Schmeiser HH
Carcinogenesis; 2003 Oct; 24(10):1695-703. PubMed ID: 12869422
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenic aristolochic acids upon activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Frei E; Sopko B; Wiessler M; Schmeiser HH
Carcinogenesis; 2002 Apr; 23(4):617-25. PubMed ID: 11960915
[TBL] [Abstract][Full Text] [Related]
3. Human hepatic and renal microsomes, cytochromes P450 1A1/2, NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer.
Stiborová M; Frei E; Hodek P; Wiessler M; Schmeiser HH
Int J Cancer; 2005 Jan; 113(2):189-97. PubMed ID: 15386410
[TBL] [Abstract][Full Text] [Related]
4. Comparison of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and N-acetyltranferases.
Martinek V; Kubickova B; Arlt VM; Frei E; Schmeiser HH; Hudecek J; Stiborova M
Neuro Endocrinol Lett; 2011; 32 Suppl 1():57-70. PubMed ID: 22167209
[TBL] [Abstract][Full Text] [Related]
5. Carcinogenic and nephrotoxic alkaloids aristolochic acids upon activation by NADPH : cytochrome P450 reductase form adducts found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Hájek M; Frei E; Schmeiser HH
Gen Physiol Biophys; 2001 Dec; 20(4):375-92. PubMed ID: 11989648
[TBL] [Abstract][Full Text] [Related]
6. The binding of aristolochic acid I to the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this human carcinogen.
Stiborová M; Sopko B; Hodek P; Frei E; Schmeiser HH; Hudecek J
Cancer Lett; 2005 Nov; 229(2):193-204. PubMed ID: 16125300
[TBL] [Abstract][Full Text] [Related]
7. Evidence for reductive activation of carcinogenic aristolochic acids by prostaglandin H synthase -- (32)P-postlabeling analysis of DNA adduct formation.
Stiborová M; Frei E; Breuer A; Wiessler M; Schmeiser HH
Mutat Res; 2001 Jun; 493(1-2):149-60. PubMed ID: 11516724
[TBL] [Abstract][Full Text] [Related]
8. The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases.
Stiborová M; Mareš J; Frei E; Arlt VM; Martínek V; Schmeiser HH
Environ Mol Mutagen; 2011 Jul; 52(6):448-59. PubMed ID: 21370283
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy.
Stiborová M; Frei E; Arlt VM; Schmeiser HH
Mutat Res; 2008; 658(1-2):55-67. PubMed ID: 17851120
[TBL] [Abstract][Full Text] [Related]
10. Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver.
Stiborova M; Mares J; Levova K; Pavlickova J; Barta F; Hodek P; Frei E; Schmeiser HH
Neuro Endocrinol Lett; 2011; 32 Suppl 1():121-30. PubMed ID: 22167220
[TBL] [Abstract][Full Text] [Related]
11. The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats--a comparative study.
Bárta F; Levová K; Frei E; Schmeiser HH; Arlt VM; Stiborová M
Mutat Res Genet Toxicol Environ Mutagen; 2014 Jul; 768():1-7. PubMed ID: 24769487
[TBL] [Abstract][Full Text] [Related]
12. The role of biotransformation enzymes in the development of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Stiborova M; Frei E; Arlt VM; Schmeiser HH
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):5-11. PubMed ID: 19365519
[TBL] [Abstract][Full Text] [Related]
13. Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model.
Levová K; Moserová M; Kotrbová V; Sulc M; Henderson CJ; Wolf CR; Phillips DH; Frei E; Schmeiser HH; Mares J; Arlt VM; Stiborová M
Toxicol Sci; 2011 May; 121(1):43-56. PubMed ID: 21362632
[TBL] [Abstract][Full Text] [Related]
14. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures.
Stiborová M; Fernando RC; Schmeiser HH; Frei E; Pfau W; Wiessler M
Carcinogenesis; 1994 Jun; 15(6):1187-92. PubMed ID: 8020154
[TBL] [Abstract][Full Text] [Related]
15. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy.
Bieler CA; Stiborova M; Wiessler M; Cosyns JP; van Ypersele de Strihou C; Schmeiser HH
Carcinogenesis; 1997 May; 18(5):1063-7. PubMed ID: 9163697
[TBL] [Abstract][Full Text] [Related]
16. Aristolactam I a metabolite of aristolochic acid I upon activation forms an adduct found in DNA of patients with Chinese herbs nephropathy.
Stiborová M; Frei E; Breuer A; Bieler CA; Schmeiser HH
Exp Toxicol Pathol; 1999 Jul; 51(4-5):421-7. PubMed ID: 10445409
[TBL] [Abstract][Full Text] [Related]
17. Environmental pollutant and potent mutagen 3-nitrobenzanthrone forms DNA adducts after reduction by NAD(P)H:quinone oxidoreductase and conjugation by acetyltransferases and sulfotransferases in human hepatic cytosols.
Arlt VM; Stiborova M; Henderson CJ; Osborne MR; Bieler CA; Frei E; Martinek V; Sopko B; Wolf CR; Schmeiser HH; Phillips DH
Cancer Res; 2005 Apr; 65(7):2644-52. PubMed ID: 15805261
[TBL] [Abstract][Full Text] [Related]
18. The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats.
Stiborová M; Levová K; Bárta F; Šulc M; Frei E; Arlt VM; Schmeiser HH
Mutagenesis; 2014 May; 29(3):189-200. PubMed ID: 24598128
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Aristolochic acid I derived DNA adduct levels in human renal toxicity models.
Bastek H; Zubel T; Stemmer K; Mangerich A; Beneke S; Dietrich DR
Toxicology; 2019 May; 420():29-38. PubMed ID: 30940547
[TBL] [Abstract][Full Text] [Related]
20. Enzymes metabolizing aristolochic acid and their contribution to the development of aristolochic acid nephropathy and urothelial cancer.
Stiborová M; Martínek V; Frei E; Arlt VM; Schmeiser HH
Curr Drug Metab; 2013 Jul; 14(6):695-705. PubMed ID: 23701164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
